Search Results

Rapid Arc Dynamic Precision Radiotherapy Technology Launched in Western New South Wales, Australia

Cancer patients in western New South Wales, Australia, have recently gained a new radiotherapy option. The Western New South Wales Local Health District has introduced Rapid Arc Dynamic (RAD) technology at the Western Cancer Centre at Dubbo Health Service, becoming the first public health institution in Australia to offer this service. According to reports, RAD is a highly precise and personalized radiotherapy technology that can help clinicians more accurately target tumor areas while minimizing radiation exposure to surrounding healthy tissue. This technology is suitable for a variety of treatment scenarios, particularly for patients with longer tumor extents and lymph node metastases. R...

2026-09-10

Assam, India, Plans to Introduce Proton Beam Therapy for Cancer Treatment at a Public Hospital

Cancer treatment capabilities in Assam, India, are set to be upgraded. Assam Chief Minister Himanta Biswa Sarma announced that the state cabinet has approved the introduction of a proton beam therapy system at Gauhati Medical College Hospital. Once the project is completed, Assam will become the third region in India to offer proton beam therapy, and the hospital will be the first public hospital in India to be equipped with this technology. Currently, proton beam therapy is already in use at the Tata Memorial Centre in Mumbai and the Apollo Proton Cancer Centre in Chennai. The facility planned at Gauhati Medical College Hospital will become the third such treatment center in India. Proton beam therapy is an advanced form of radiotherapy used to treat cancer and certain non-cancerous tumors. Unlike conventional radiation therapy, which typically uses X-rays, proton therapy delivers precise irradiation to the tumor area using high-energy positively charged particles—protons. As proton beams enter the body, they release energy, causing DNA damage to cells. Healthy cells generally possess some capacity for repair, whereas cancer cells are less able to repair themselves, thereby inhibiting their growth and proliferation and helping to destroy tumor tissue.

2026-08-31

Blueprint for Proton Therapy Center in Southeastern Busan, South Korea Unveiled to Address Regional Gap in Cancer Treatment Resources

The blueprint for the proton therapy center at the Southeastern Regional Nuclear Medicine Center in Gijang-gun, Busan, South Korea, was recently unveiled. The project is expected to help bridge the gap in cancer treatment resources between the Seoul metropolitan area and non-capital regions, and to promote the application of proton accelerators in high-tech industries. According to information from Gijang-gun, Busan, and the Southeastern Regional Institute of Radiation Medicine on August 29, the Busan Institute of Science and Technology Higher Education recently published a service report titled "Establishment of Promotion Strategy and Implementation Plan for the Southeastern Proton Therapy Center," which includes the construction blueprint and feasibility analysis of the center. The Southeastern Regional Institute of Radiation Medicine is advancing related preparatory work in response to the research and development review by the Ministry of Science and ICT in the second half of this year...

2026-08-30

Hyogo Medical University Hospital to Launch Japan's First Elekta Evo Linear Accelerator System Treatments

Elekta K.K. announced on August 27 that its high-precision radiation therapy device, the Elekta Evo linear accelerator system, will be installed for the first time in Japan at Hyogo Medical University Hospital, with the first treatment scheduled to commence on September 24, 2026. This marks the entry of this next-generation radiation therapy system into clinical application in Japan. As the number of cancer patients increases, the demand for personalized and precise treatment in the field of radiation therapy continues to rise. The Elekta Evo is positioned as a next-generation radiation therapy system capable of covering both routine and more complex cancer treatment scenarios. The system is equipped with Iris, an AI-driven high-definition imaging technology, which enables clearer visualization of the positional relationships between organs in the patient's body...

2026-08-27

South Korean lawmaker calls for heavy ion therapy center in Daejeon to ease regional cancer treatment disparities

South Korean lawmaker Park Yong-gap recently called on the government to support the construction of a heavy ion therapy center in the central region of Daejeon, aiming to improve access to advanced radiation therapy for cancer patients outside the capital area and promote a balanced distribution of regional medical resources. Park stated that heavy ion therapy centers are often referred to as "dream cancer treatment centers." Compared with conventional radiation therapy, heavy ion therapy and proton therapy can target cancer cells more precisely while minimizing impact on surrounding normal tissues, making them advanced particle therapy technologies drawing attention in the current cancer treatment field. According to him, the relevant treatment centers currently in operation in South Korea are mainly concentrated in the capital area, including the heavy ion therapy center at Sinchon Severance Hospital of Yonsei University...

2026-08-26

South Korea Advances First Domestic Commercial Production of Lu-177 Using Wolsong Heavy Water Reactors

Korea Hydro & Nuclear Power (KHNP) plans to use the heavy water reactors at the Wolsong Nuclear Power Plant to produce, for the first time domestically, the radioisotope lutetium-177 (Lu-177) for cancer treatment. Currently, South Korea relies entirely on imports for this material, which imposes cost pressures and supply instability on local radiopharmaceutical companies such as Cellbion and FutureChem. Industry experts generally believe that domestic production will help build a diversified supply chain and shorten transportation times. The primary goal of this plan is to achieve commercial production of Lu-177, with pilot production expected in 2028 and full-scale production commencing in 2031. Subsequently, KHNP will expand production to include cobalt...

2026-08-06

Santa Casa Hospital in Ceará, Brazil, Introduces New Linear Accelerator for Cancer Treatment

Santa Casa de Sobral Hospital in northern Ceará, Brazil, has introduced a new linear accelerator to strengthen cancer treatment for patients in the northern region. The hospital received a new linear accelerator for radiotherapy of cancer patients. After completing the installation, training, and licensing processes, this new technology is expected to double the institution's radiotherapy capacity, increasing from the current 600 patients per month to approximately 1,200 new patients. This equipment, the Halcyon linear accelerator, is considered the latest technology in radiotherapy and is the second unit of its kind installed in Ceará. The device is capable of providing faster, more precise, and safer treatment for various types of cancer...

2026-08-01

Russian State Expert Review Authority Approves Design Changes for Ufa Radionuclide Therapy Center

Russia approves design changes for the Ufa Radionuclide Therapy Center, which will employ the latest technologies and equipment. The new center, located in the Republic of Bashkortostan, is expected to become a significant force in the local fight against cancer. With a floor area exceeding 6,000 square meters, the facility is a G-shaped three-story building with a basement. Its internal framework uses monolithic reinforced concrete to ensure stability and safety. The project's design strictly adheres to medical technology standards, aiming to create a modern and innovative treatment institution. At the core of the center is the radionuclide therapy department, which includes 24-hour inpatient wards, featuring a radionuclide supply area, a 20-bed "active" ward, and common areas. Additionally, it includes service and administrative zones to support the center's daily operations...

2026-08-01

TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility

TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...

2026-07-30